goserelin and Breast-Diseases

Breast pain is a common symptom in patients attending breast clinics. The purpose of this study was to evaluate the efficacy of goserelin (Zoladex) as compared with sham injection in patients with mastalgia.. One hundred forty-seven premenopausal women were randomized to treatment with either goserelin injection (3.6 mg/month) or sham injection for a total of 6 injections. Patients' daily self-assessment of breast pain using Cardiff breast pain chart was recorded during the 6-month treatment period and for 6 months in the posttreatment period.. A significant treatment difference between the 2 groups in favor of goserelin was noted during the treatment period. Mean breast pain score improved by 67% in the goserelin group and 35% in the sham group during the treatment period. The mean pain scores increased in both groups in the posttreatment period. No significant posttreatment difference was found between the two groups. Side effects were more common with goserelin than sham injection. Patients receiving goserelin experienced vaginal dryness, hot flushes, decreased libido, oily skin or hair, and a decrease in breast size more frequently than sham patients.. Goserelin is an effective short-term treatment for mastalgia. However, side effects are common, and thus, goserelin should be kept in reserve for patients who are refractory to other forms of treatment. Potentially, goserelin could be used to induce a rapid relief of symptoms that could be maintained with alternative therapies.

Topics: Adult; Analysis of Variance; Breast Diseases; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Follow-Up Studies; Goserelin; Humans; Injections, Subcutaneous; Middle Aged; Pain; Pain Measurement; Patient Satisfaction; Probability; Risk Assessment; Severity of Illness Index; Treatment Outcome

Topics: Adult; Alopecia; Breast Diseases; Estrogen Antagonists; Female; Goserelin; Humans; Pain; Tamoxifen

Topics: Anti-Inflammatory Agents, Non-Steroidal; Breast Diseases; Bromocriptine; Danazol; Fatty Acids, Essential; Female; gamma-Linolenic Acid; Goserelin; Humans; Linoleic Acids; Oenothera biennis; Pain; Periodicity; Plant Oils; Premenstrual Syndrome; Tamoxifen

Mild breast pain and nodularity are common and may be considered normal. Only when symptoms are severe enough to affect the patient's lifestyle should drug treatment be considered. Using danazol, bromocriptine or evening primrose oil a clinically useful improvement in pain can be anticipated in 77% of patients with cyclical mastalgia and 44% with non-cyclical mastalgia. Benign nodularity should not be biopsied surgically as it is unnecessary and makes subsequent assessment of the breast difficult.

Topics: Adult; Age Factors; Breast Diseases; Bromocriptine; Buserelin; Danazol; Estrogen Replacement Therapy; Fatty Acids, Essential; Female; gamma-Linolenic Acid; Goserelin; Humans; Hypolipidemic Agents; Linoleic Acids; Oenothera biennis; Pain; Plant Oils; Tamoxifen